These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 34017122)

  • 1. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape.
    de Jong MME; Kellermayer Z; Papazian N; Tahri S; Hofste Op Bruinink D; Hoogenboezem R; Sanders MA; van de Woestijne PC; Bos PK; Khandanpour C; Vermeulen J; Moreau P; van Duin M; Broijl A; Sonneveld P; Cupedo T
    Nat Immunol; 2021 Jun; 22(6):769-780. PubMed ID: 34017122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
    Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL; Hofmeister CC; Boise LH; Lonial S; Kemp ML; Dhodapkar KM; Dhodapkar MV
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-evolution of tumor and immune cells during progression of multiple myeloma.
    Liu R; Gao Q; Foltz SM; Fowles JS; Yao L; Wang JT; Cao S; Sun H; Wendl MC; Sethuraman S; Weerasinghe A; Rettig MP; Storrs EP; Yoon CJ; Wyczalkowski MA; McMichael JF; Kohnen DR; King J; Goldsmith SR; O'Neal J; Fulton RS; Fronick CC; Ley TJ; Jayasinghe RG; Fiala MA; Oh ST; DiPersio JF; Vij R; Ding L
    Nat Commun; 2021 May; 12(1):2559. PubMed ID: 33963182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
    Van Oekelen O; Amatangelo M; Guo M; Upadhyaya B; Cribbs AP; Kelly G; Patel M; Kim-Schulze S; Flynt E; Lagana A; Gooding S; Merad M; Jagganath S; Pierceall WE; Oppermann U; Thakurta A; Parekh S
    Cell Rep Med; 2024 Jun; 5(6):101584. PubMed ID: 38776911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.
    Tirier SM; Mallm JP; Steiger S; Poos AM; Awwad MHS; Giesen N; Casiraghi N; Susak H; Bauer K; Baumann A; John L; Seckinger A; Hose D; Müller-Tidow C; Goldschmidt H; Stegle O; Hundemer M; Weinhold N; Raab MS; Rippe K
    Nat Commun; 2021 Nov; 12(1):6960. PubMed ID: 34845188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
    Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
    Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
    Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
    Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
    Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
    Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.
    de Jong MME; Fokkema C; Papazian N; Czeti Á; Appelman MK; Vermeulen M; van Heusden T; Hoogenboezem RM; van Beek G; Tahri S; Sanders MA; van de Woestijne PC; Gay F; Moreau P; Büttner-Herold M; Bruns H; van Duin M; Broijl A; Sonneveld P; Cupedo T
    Nat Immunol; 2024 May; 25(5):820-833. PubMed ID: 38600356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
    Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
    Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes.
    Binder M; Szalat RE; Talluri S; Fulciniti M; Avet-Loiseau H; Parmigiani G; Samur MK; Munshi NC
    Nat Commun; 2024 May; 15(1):4139. PubMed ID: 38755155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro.
    Cheung WC; Van Ness B
    Leukemia; 2001 Feb; 15(2):264-71. PubMed ID: 11236942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
    Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
    Ria R; Vacca A
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response.
    Cascini C; Chiodoni C
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment.
    Ponzetta A; Benigni G; Antonangeli F; Sciumè G; Sanseviero E; Zingoni A; Ricciardi MR; Petrucci MT; Santoni A; Bernardini G
    Cancer Res; 2015 Nov; 75(22):4766-77. PubMed ID: 26438594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.